Jacob Keane-Candib
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jacob Keane-Candib has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Joshua Aiden Hill
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington
4 shared publications - Andrew J. Cowan
Fred Hutchinson Cancer Center, Seattle, WA
3 shared publications - Damian J. Green
Department of Medicine, Division of Transplantation and Cellular Therapy, Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA
3 shared publications Gregory Pepper
Department of Laboratory Medicine, University of Washington, Seattle, WA
2 shared publications- Jim Boonyaratanakornkit
Fred Hutchinson Cancer Center
2 shared publications - Sayan Dasgupta
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center , Seattle, WA
2 shared publications
Latest Publications
- Open Access
- 12 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (3) , 416-422
Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy
- 12 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (3) , 416-422
Open AccessAnti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy
- Open Access
- 11 March 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (6) , 304.e1-304.e9
Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma
- 11 March 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (6) , 304.e1-304.e9
Open AccessPathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma
- Open Access
- 8 June 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (11)
Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies
BACKGROUND: Little is known about pathogen-specific humoral immunity after chimeric antigen receptor–modified T (CAR-T) cell therapy for B cell malignancies. METHODS: We conducted a prospective cross-sectional study of CD19-targeted or B cell maturation antigen–targeted (BCMA-targeted) CAR-T cell therapy recipients at least 6 months posttreatment and in remission. We measured pathogen-specific IgG against 12 vaccine-preventable infections and the number of viral and bacterial epitopes to which IgG was detected (“epitope hits”) using a serological profiling assay. The primary outcome was the proportion of participants with IgG levels above a threshold correlated with seroprotection for vaccine-preventable infections. RESULTS: We enrolled 65 children and adults a median of 20 months after CD19- ( n = 54) or BCMA- ( n = 11) CAR-T cell therapy. Among 30 adults without IgG replacement therapy (IGRT) in the prior 16 weeks, 27 (90%) had hypogammaglobulinemia. These individuals had seroprotection to a median of 67% (IQR, 59%–73%) of tested infections. Proportions of participants with seroprotection per pathogen were comparable to population-based studies, but most individuals lacked seroprotection to specific pathogens. Compared with CD19-CAR-T cell recipients, BCMA-CAR-T cell recipients were half as likely to have seroprotection (prevalence ratio, 0.47; 95% CI, 0.18–1.25) and had fewer pathogen-specific epitope hits (mean difference, –90 epitope hits; 95% CI, –157 to –22). CONCLUSION: Seroprotection for vaccine-preventable infections in adult CD19-CAR-T cell recipients was comparable to the general population. BCMA-CAR-T cell recipients had fewer pathogen-specific antibodies. Deficits in both groups support the need for vaccine and immunoglobulin replacement therapy studies. FUNDING: Swiss National Science Foundation (Early Postdoc Mobility grant P2BSP3_188162), NIH/National Cancer Institute (NIH/NCI) (U01CA247548 and P01CA018029), NIH/NCI Cancer Center Support Grants (P30CA0087-48 and P30CA015704-44), American Society for Transplantation and Cellular Therapy, and Juno Therapeutics/BMS.
- 8 June 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (11)
Open AccessAntibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies
BACKGROUND: Little is known about pathogen-specific humoral immunity after chimeric antigen receptor–modified T (CAR-T) cell therapy for B cell malignancies. METHODS: We conducted a prospective cross-sectional study of CD19-targeted or B cell maturation antigen–targeted (BCMA-targeted) CAR-T cell therapy recipients at least 6 months posttreatment and in remission. We measured pathogen-specific IgG against 12 vaccine-preventable infections and the number of viral and bacterial epitopes to which IgG was detected (“epitope hits”) using a serological profiling assay. The primary outcome was the proportion of participants with IgG levels above a threshold correlated with seroprotection for vaccine-preventable infections. RESULTS: We enrolled 65 children and adults a median of 20 months after CD19- ( n = 54) or BCMA- ( n = 11) CAR-T cell therapy. Among 30 adults without IgG replacement therapy (IGRT) in the prior 16 weeks, 27 (90%) had hypogammaglobulinemia. These individuals had seroprotection to a median of 67% (IQR, 59%–73%) of tested infections. Proportions of participants with seroprotection per pathogen were comparable to population-based studies, but most individuals lacked seroprotection to specific pathogens. Compared with CD19-CAR-T cell recipients, BCMA-CAR-T cell recipients were half as likely to have seroprotection (prevalence ratio, 0.47; 95% CI, 0.18–1.25) and had fewer pathogen-specific epitope hits (mean difference, –90 epitope hits; 95% CI, –157 to –22). CONCLUSION: Seroprotection for vaccine-preventable infections in adult CD19-CAR-T cell recipients was comparable to the general population. BCMA-CAR-T cell recipients had fewer pathogen-specific antibodies. Deficits in both groups support the need for vaccine and immunoglobulin replacement therapy studies. FUNDING: Swiss National Science Foundation (Early Postdoc Mobility grant P2BSP3_188162), NIH/National Cancer Institute (NIH/NCI) (U01CA247548 and P01CA018029), NIH/NCI Cancer Center Support Grants (P30CA0087-48 and P30CA015704-44), American Society for Transplantation and Cellular Therapy, and Juno Therapeutics/BMS.
- Open Access
- 1 March 2021
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 27 (3) , S345-S346
Infectious Complications and Humoral Immunity after BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy in Adults with Multiple Myeloma
- 1 March 2021
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 27 (3) , S345-S346
Open AccessInfectious Complications and Humoral Immunity after BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy in Adults with Multiple Myeloma